๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Ultra-hypofractioNated Adjuvant Radiotherapy ยฑ sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
NCT05762900Breast Cancer, Radiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
65
Beijing
2022-10-25
Active, closed
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
BeiGene
Phase 2
100
Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan
2022-10-25
Recruiting
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
NCT06617000HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma
SCG Cell Therapy Pte. Ltd.
Phase 1
38
Beijing, Guangzhou, Zhengzhou, Changchun, Shenyang, Ji'nan, Shanghai
2022-10-25
By invitation
Development Platform Construction and Application Promotion of Drug-Eluting Stents for Intracranial Aneurysm Interventional Therapy
NCT07190781Cerebral Aneurysm Unruptured
Xinjian Yang
Observational
280
Beijing
2022-10-24
Recruiting
To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.
NCT04944615Chronic Total Occlusion of Coronary Artery
CCRF Inc., Beijing, China
Not applicable
1,448
Beijing
2022-10-21
Active, closed
Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
NCT05869123Uterine Cervical Neoplasm, Endometrial Neoplasms
Peking Union Medical College Hospital
Phase 1/2
17
Beijing
2022-10-20
Active, closed
Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China
NCT07264478RSV Infection, Disease Burden
Beijing Children's Hospital
Observational
1,100
Beijing
2022-10-15
Active, closed
LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB
NCT05572957Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block
The First Affiliated Hospital with Nanjing Medical University
Not applicable
50
Beijing, Fuzhou, Nanjing, Dalian, Chengdu, Wenzhou
2022-10-14
Recruiting
Neuraxial Labor Analgesia and Offspring Neurodevelopment
NCT04964206Pregnant Women, Labor Pain, Analgesia, Epidural, Infants
Dong-Xin Wang
Observational
4,645
Beijing, Shenzhen
2022-10-14
Recruiting
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
NCT05761366Malignancy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
400
Beijing
2022-10-13
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
864
Beijing, Changchun, Changsha, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2022-10-13
Recruiting
KSH01-R02-101 Solid Tumors
NCT05580796Solid Tumor
TCRx Therapeutics Co.Ltd
Phase EARLY_PHASE1
50
Beijing
2022-10-11
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
Eli Lilly and Company
Phase 3
15,374
Beijing, Changchun, Changping, Chengdu, Chongqing, Haikou, Harbin, Hengshui Shi
2022-10-11
Active, closed
Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population
NCT05462262Coronary Artery Disease Progression
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
2,900
Beijing
2022-10-10
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou Fujian, Guangzhou, Haidian District
2022-10-10
Active, closed
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
NCT07226752Diffuse Large B-Cell Lymphoma
Genmab
Phase 3
72
Baoding, Beijing, Changchun, Chengdu, Dalian, Guandong, Guangxi, Hangzhou
2022-10-08
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Anyang, Baoding, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang
2022-10-04
Active, closed
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
Novartis Pharmaceuticals
Phase 1
61
Beijing, Shanghai, Tianjin
2022-10-03
Recruiting
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
NCT06202001Metastatic Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
70
Beijing
2022-10-01
Recruiting
Myopia Preventing With Distance-image Screen
NCT06088225Myopia, Progressive
Beijing Airdoc Technology Co., Ltd.
Not applicable
100
Beijing
2022-10-01
Recruiting
Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks
NCT05230017Anti Phospholipid Syndrome
Peking Union Medical College Hospital
Observational
2,000
Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Hohhot, Nanjing, Nanchang
2022-10-01
Recruiting
Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study
NCT05576389Germline BRCA-mutated HER2-negative Breast Cancer
Peking University People's Hospital
Phase 2
64
Beijing
2022-10-01
Recruiting
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
NCT06092125Alzheimer Disease, Parkinson Disease, Epilepsy, Malignant Brain Tumor
Xuanwu Hospital, Beijing
Observational
2,300
Beijing
2022-10-01
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05503264NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Hoffmann-La Roche
Phase 3
122
Beijing, Chengdu, Fuzhou, Jining, Shanghai, Wenzhou
2022-09-27
Recruiting
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05623982Non-hodgkin's Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
40
Beijing, Haerbin, Qingdao
2022-09-26
Recruiting
APP-based Precise Management System of Chronic Intractable Pain
NCT05761392Pain, Chronic, Pain, Intractable
Beijing Tsinghua Chang Gung Hospital
Not applicable
120
Beijing
2022-09-26
Active, closed
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
NCT05514132Advanced Solid Tumours
AstraZeneca
Phase 1
14
Beijing, Shandong
2022-09-23
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LLC
Phase 2/3
201
Beijing, Changchun, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Jinan
2022-09-23
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066Follicular Lymphoma (FL)
Genmab
Phase 3
549
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2022-09-20
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
Celgene
Phase 3
810
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Shijiazhuang
2022-09-20
Recruiting
RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2
NCT05403242Advanced Gastroesophageal Adenocarcinoma
Chinese PLA General Hospital
Phase 1/2
42
Beijing
2022-09-20
Recruiting
DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
NCT05517291Safety Issues, Efficacy, Self
Peking Union Medical College Hospital
Not applicable
200
Beijing
2022-09-18
Active, closed
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327Systemic Lupus Erythematosus
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
379
Baotou, Beijing, Changchun, Guangzhou, Haikou, Luoyang, Nanchang, Nanjing
2022-09-16
Active, closed
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
594
Baoding, Beijing, Changsha, Chengdu, Deyang, Guangzhou, Hangzhou, Hefei
2022-09-15
Recruiting
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
NCT06954961Breast Cancer
InventisBio Co., Ltd
Phase 3
640
Beijing, Harbin
2022-09-15
Active, closed
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen
Phase 2/3
450
Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shenzhen, Zhongshan, Nanyang
2022-09-13
Recruiting
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505MRD
Guangdong Association of Clinical Trials
Phase 2
180
Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei
2022-09-13
Recruiting
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
NCT05512481Melanoma, Acral Melanoma, Temozolomide, Apatinib
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2022-09-13
Active, closed
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
418
Beijing, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou, Hefei, Jinhua
2022-09-13
Recruiting
Children to Adults Mental and Psychosomatic Health Study (CAMPS)
NCT05621278Mental Health Wellness, Cognitive Function, Physical Symptoms
Peking University
Observational
400,000
Beijing
2022-09-11
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Recruiting
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368Hypereosinophilic Syndrome
GlaxoSmithKline
Phase 3
109
Beijing, Changsha, Guangzhou, Harbin, Nanchang, Shanghai, Suzhou, Wuhan
2022-09-06
Recruiting
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
NCT06014528Ovarian Cancer Recurrent
InxMed (Shanghai) Co., Ltd.
Phase 2
168
Beijing
2022-09-06
Active, closed
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
BeiGene
Phase 1/2
125
Hefei, Beijing, Fuzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Haikou
2022-09-05
Recruiting
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
NCT05824871Rifampin-Resistant Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant (MDR-TB)
Shanghai Jiatan Pharmatech Co., Ltd
Phase 3
450
Beijing
2022-09-02
Recruiting
Study on the Mechanism of Eating Disorder
NCT05862389Anorexia Nervosa, Bulimia Nervosa
Peking University
Observational
750
Beijing
2022-09-01
Recruiting
The Evolution and Prognosis of Moyamoya Disease
NCT05619068Moyamoya Disease, Revascularization, Cognitive Impairment, Functional Impairment
Chinese PLA General Hospital
Observational
300
Beijing
2022-09-01
Recruiting
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05168566Non-small Cell Lung Cancer
Teligene US
Phase 2
99
Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2022-09-01
Active, closed
Optimization of Cervical Nodal CTV for Early and Medium Stage NPC
NCT05145660Nasopharyngeal Carcinoma
Yi Junlin
Phase 3
414
Beijing
2022-09-01
Recruiting
Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson's Disease
NCT06710574Parkinson Disease, Movement Disorders, Rapid Eye Movement Sleep Behavior Disorder, Gut Microbiomes
Beijing Friendship Hospital
Phase 4
120
Beijing
2022-09-01
Recruiting
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
NCT05514327Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy, Bridging Therapy
Peking Union Medical College Hospital
Not applicable
20
Beijing
2022-09-01
Not yet open
Non-invasive Transcranial Focused Low-intensity Ultrasound Stimulation in Patients With Mild Lewy Body Dementia
NCT05499429Lewy Body Dementia
Xuanwu Hospital, Beijing
Not applicable
20
Beijing
2022-09
Active, closed
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
NCT05459844Neuroendocrine Tumors
Sinotau Pharmaceutical Group
Phase 3
196
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun
2022-08-31
Not yet open
To Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment of Patients With Moderately Severe and Severe Functional Mitral Regurgitation(FMR) Who Remained Clinically Symptomatic After Guideline-directed Medical Treatment
NCT05508438Mitral Valve Insufficiency
Pan Xiangbin
Not applicable
140
Beijing
2022-08-30
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals
Phase 4
347
Chongqing, Guangzhou, Zhengzhou, Wuhan, Changchun, Xian, Chengdu, Beijing
2022-08-30
Recruiting
Early Warning and Classification Model for Acute Non-traumatic Chest Pain
NCT06196307Chest Pain
Xiao-nan He
Observational
10,000
Beijing
2022-08-30
Recruiting
China HeadAche DIsorders RegiStry
NCT05334927Headache Disorders, Primary, Migraine, New Daily Persistent Headache, Medication Overuse Headache
Beijing Tiantan Hospital
Observational
10,000
Anqing, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Shenzhen
2022-08-29
Active, closed
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
NCT05518045Advanced Solid Tumor
LaNova Medicines Limited
Phase 1/2
392
Beijing
2022-08-26
Recruiting
Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma
NCT06163729Gastroesophageal Junction Adenocarcinoma (Siewert II-III)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
68
Beijing
2022-08-25
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
NCT05473624Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
Sanofi
Phase 2/3
1,856
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang
2022-08-22
Active, closed
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
NCT05413018Leukemia, Myeloid, Acute
Bristol-Myers Squibb
Phase 2
34
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Shijiazhuang, Xuzhou, Shenyang
2022-08-19
Active, closed
A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT05314010Neuromyelitis Optica Spectrum Disorder
Beijing Mabworks Biotech Co., Ltd.
Phase 3
102
Beijing
2022-08-18
Recruiting
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
NCT05276726Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Recruiting
68Ga-RM26-RGD PET/CT Imaging in the GRPR and ฮฑvฮฒ3 Positive Tumor Patients
NCT05549024Breast Cancer, Prostate Cancer, Brain Tumor, PET/CT Imaging
Peking Union Medical College Hospital
Phase EARLY_PHASE1
90
Beijing
2022-08-16
Active, closed
PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas
NCT05473923Recurrent High Grade Glioma
Beijing Tiantan Hospital
Phase EARLY_PHASE1
30
Beijing
2022-08-12
Recruiting
68Ga-N188 PET/CT Imaging in Malignancy
NCT05593107Neoplasms
Peking University First Hospital
Not applicable
203
Beijing
2022-08-12
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
240
Nanning, Wuhan, Shenyang, Yinchuan, Beijing, Shenzhen
2022-08-10
Active, closed
A Research Study to Compare Somapacitan Once a Week With Norditropinยฎ Once a Day in Children Who Need Help to Grow
NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS
Novo Nordisk A/S
Phase 3
412
Beijing, Guangzhou, Liuzhou, Sanya, Zhengzhou, Wuhan, Changsha, Changchun
2022-08-10
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
NCT05299424Multiple Myeloma
Keymed Biosciences Co.Ltd
Phase 1/2
48
Beijing
2022-08-09
Not yet open
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
NCT05484024Rectal Neoplasms Malignant, Radiotherapy
Chinese Academy of Medical Sciences
Phase 2/3
588
Beijing, Shenzhen
2022-08-06
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Recruiting
The Beijing Angle Closure Progression Study
NCT05563623Angle-Closure Glaucoma
Peking University People's Hospital
Observational
825
Beijing
2022-08-04
Recruiting
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou
2022-08-03
Active, closed
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1
276
Beijing, Guangzhou, Wuhan
2022-08-03
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
341
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2022-08-03
Recruiting
Chinese Colorectal Cancer Database
NCT05434026Colonic Cancer, Rectal Cancer, Prospective Studies
Beijing Friendship Hospital
Observational
200,000
Beijing
2022-08-03
Recruiting
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
NCT06732531Bladder Cancer, Non Muscle Invasive
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Recruiting
Health-Related Quality of Life and Emotions in Patients with Thyroid Nodules
NCT06610604Thyroid Nodule
Ming-an Yu
Observational
500
Beijing
2022-08-01
Recruiting
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
NCT06087068Thyroid Cancer, Surgery, Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
140
Beijing
2022-08-01
Recruiting
Lung Health of Early COPD: A Multi-center Cohort Study
NCT05466396COPD
Ting YANG
Observational
1,550
Beijing, Zunyi
2022-08-01
Recruiting
TreAtments and outComes in paTients With prImary CutAneous Lymphoma
NCT05518851Primary Cutaneous Lymphoma
Peking University First Hospital
Observational
3,000
Beijing, Guandong, Nanjing, Jinan
2022-08-01
Recruiting
Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
NCT07328230Idiopathic Hyperaldosteronism, Hyperaldosteronism
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
172
Beijing, Nanchang, Chengdu
2022-08-01
Recruiting
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
NCT05888909Diabetic Nephropathy Type 2, Diabetic Kidney Disease, Type 2 Diabetes
Chinese PLA General Hospital
Observational
2,000
Beijing
2022-08-01
Active, closed
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
NCT05133531Paroxysmal Nocturnal Hemoglobinuria
Regeneron Pharmaceuticals
Phase 3
202
Beijing
2022-08-01
By invitation
Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA
NCT07299123Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Refractory, Severe Aplastic Anemia
Chinese PLA General Hospital
Phase 1/2
40
Beijing
2022-08-01
Recruiting
Clinical Indicators and Brain Image Data: a Study Based on Kailuan Cohort
NCT05453877Brain Diseases, Hypertension
Beijing Friendship Hospital
Observational
1,000
Beijing, Tangshan
2022-08-01
Recruiting
Lateral Pelvic Lymph Node Dissection for Rectal Neuroendocrine Neoplasms Undergoing Laparoscopic Total Mesenteric Excision
NCT06279299Rectal Neuroendocrine Neoplasm
National Cancer Center, China
Not applicable
30
Beijing
2022-08-01
Recruiting
Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration
NCT05445063Macular Degeneration
Beijing Tongren Hospital
Phase 1
10
Beijing
2022-08
Active, closed
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
NCT05457257Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 4
43
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-07-29
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
NCT05899049Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Haikou
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Recruiting
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348Myasthenia Gravis, Generalized
Tang-Du Hospital
Phase 2
64
Beijing, Changsha, Xi'an, Shanghai, Chengdu, Tianjin
2022-07-21
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
Hereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort
NCT06512376Cerebral Small Vessel Diseases, Hereditary
Beijing Tiantan Hospital
Observational
100
Beijing
2022-07-19
Not yet open
Intraperitoneal Lidocaine in Ovarian Cancer Surgery
NCT05450055Ovarian Cancer, Post Operative Pain
Peking University Third Hospital
Not applicable
60
Beijing
2022-07-18
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
922
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou
2022-07-18
Active, closed
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934Eosinophilic Granulomatosis With Polyangiitis
GlaxoSmithKline
Phase 3
163
Beijing, Guangzhou, Hefei, Nanjing, Qingdao, Shanghai, Shenzhen, Wenzhou
2022-07-14
Active, closed
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696Extensive Stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
55
Beijing, Shanghai
2022-07-13
Rows per page Showing 4501–4600 of 5484
Previous 44 45 46 47 48 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=46

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.